Ann: Appendix 4C - quarterly, page-54

Not sure what all the fuss is about...read upcoming trials in the qtly and there is a soft lock on the Hervaxx trial for interim release...if this comes in and shows efficacy...you’d have to punt that the final results will replicate what Leslie has described as beautiful data. As a standard of care replacement for TCell which has Keytruda selling $US12Billion a year and TCell collectively well north of $US20Billion a year.
The upside of this is, is not sure what to say...but if Axel Hoos who bought this science from Ursula Wiedermann in Vienna Austria to Australia...and then a smart young entrepreneur Leslie Chong from Genentech in the USA found the science on the internet and caught up with Axel in SanFran who was then at GSK USA, to drill the science and decided to join and develop a company with 5 massive shots at goal in HerVaxx, CF33x2, PD1, BVaxx...
Takes a while for the Insto’s to twig...they will...and the right ones that will Buy and Hold...it’s reaching an inflection point and I look forward to another entrepreneurial Australian company succeeding.